Melanoma PDX Models

Bring clarity to your research with our collection of well-characterized, patient-derived xenografts for melanoma.

Horizon is pleased to exclusively offer the largest collection of well-characterized patient-derived xenograft (PDX) models of melanoma available today.

We have partnered with The Wistar Institute of Anatomy and Biology in Philadelphia, Pennsylvania to make available their large collection of highly characterized Melanoma PDX models to the research community.

These melanoma models are representative of all previously well-described melanoma subtypes identified by the Cancer Genome Atlas (TCGA).

The Wistar Institute’s melanoma PDX collection has been developed by Clemens Krepler and Meenhard Herlyn. This collection has undergone a great deal of characterization, and continues to be subjected to characterization with the evolution of therapies being assessed in the research community (for example, twelve of the models in this collection have been published in Krepler, et al., Clinical Cancer Research, 2016.

PDX Cancer models

Melanoma Patient-Derived Xenografts from the Wistar Institute:

  • Over 150 PDX models of melanoma, including BRAF hotspot, RAS hotspot, NF1 mutant, KIT mutant, and Triple-WT models
  • Highly characterized models, including:
    • Comprehensive patient histories
    • Sequencing analysis data
    • Protein expression data

Wistar Melanoma Patient Derived Xenograft (PDX) Line Graph

Figure 1. Growth Curve for a Wistar Melanoma PDX model. Three NSG™ mice were implanted with minced fragments of WM4007, from mouse passage 1, subcutaneously. The growth of each individual PDX was monitored and measured using calipers.

Horizon offers a number of services around the Wistar melanoma PDX collection, including in vivo efficacy studies and viable single cell suspensions.

Now available!

Back to top